| Cat. No. |
Product Name |
Information |
| PC-25971 |
LL-K12-18
Cyclin K degrader
|
LL-K12-18 is a potent, dual-site molecular glue degrader of cyclin K with DC50 of 0.38 nM in MDA-MB-231 cells, shows anti-proliferative effect against MDA-MB-231 cell with EC50 of 37 nM, enhances CDK12-DDB1 protein interaction. |
| PC-25879 |
ZLY025
cyclin K degrader
|
ZLY025 is a highly potent, selective Cyclin K (CCNK) degrader with DC50 of 42.7 nM and Dmax>93%, exhibits broad-spectrum antitumor activity. |
| PC-25728 |
NU6140
CDK2 inhibitor
|
NU6140 is a selective inhibitor of CDK2 with IC50 of 0.41 uM for CDK2-cyclin A, 10- to 36-fold selective for CDK2-cyclin A over the other CDKs. |
| PC-25672 |
LCI133
CDK4/6/9, AURKA/B inhibitor
|
LCI133 is a highly potent, selective multikinase CDK4/6/9 and AURKA/B inhibitor with IC50 of 4.7/10.2/4.1 nM for CDK4/6/9 and 2.8/10.6 nM for AURKA/B. |
| PC-25578 |
SNX9-1-20
CDK3 inhibitor
|
SNX9-1-20 is a potent, specific cyclin-dependent kinase 3 (CDK3) inhibitor with IC50 of 164 nM, inhibits CDK3/Cyclin E with IC50 of 0.47 uM (Rb-CTF) and 0.77 uM (Histone H1), highly selective over CDK2 (>50-fold). |
| PC-25577 |
SNX9
CDK3 inhibitor
|
SNX9 is a potent, specific cyclin-dependent kinase 3 (CDK3) inhibitor. |
| PC-25576 |
SNX9-1
CDK3 inhibitor
|
SNX9-1 is a potent, specific cyclin-dependent kinase 3 (CDK3) inhibitor with IC50 of 1.58 uM, is potent in preventing the induction of transcription by p21 (IC50=15.9 uM) and growth inhibition of the HT1080-based reporter cell line (IC50=9.3 uM). |
| PC-25401 |
BRD6866
TFE3 inhibitor, CDK9 inhibitor
|
BRD6866 is a small molecule inhibitor of TFE3 transcription factor fusion activity with IC50 of 342 nM, shows dose-dependent chromatin trapping of TFE3, potent pan-CDK inhibitor across all families of CDKs, including both cell-cycle and transcriptional CDK9, suppresses tRCC cell growth. |
| PC-25380 |
LC-K2CAin-1
CDK2–Cyclin A2 inhibitor
|
LC-K2CAin-1 is a potent, highly selective CDK2-Cyclin A2 protein-protein interaction (PPI) inhibitor with IC50 of 59.57 nM in HTRF assays. |
| PC-25379 |
LC-K2CAin-3
CDK2–Cyclin A2 inhibitor
|
LC-K2CAin-3 is a potent, highly selective CDK2-Cyclin A2 protein-protein interaction (PPI) inhibitor with IC50 of 32.1 nM in HTRF assays. |
| PC-25359 |
CIRc-028
Cyclin A/B RxL inhibitor
|
CIRc-028 is a potent, in vivo-active, orally bioavailable dual cyclin A/B RxL inhibitor, inhibits cyclin A/B-RxL interactions and induces apoptosis in cancer cells with high E2F activity, induced spindle assembly checkpoint (SAC) activation and apoptosis in vivo. |
| PC-25129 |
YX0798
CDK9 inhibitor
|
YX0798 is a potent, selective and oral bioavailable CDK9 inhibitor with binding Kd of 0.28 nM, 16-50-fold more selective for CDK9 than CDK7, CDK3, or CDK4. |
